New cardinal health research highlights rheumatologists' increasing confidence in biosimilars

Dublin, ohio , oct. 19, 2022 /prnewswire/ -- today, cardinal health (nyse: cah) released its third edition of rheumatology insights , a research report based on surveys with more than 100 rheumatologists nationwide that focuses on key trends impacting one of the fastest-growing areas of specialty medicine. the research revealed that rheumatologists are both more familiar with biosimilars and more comfortable prescribing them than they were in 2020, just in time for a wave of new biosimilars anticipated to hit the market in 2023.
CAH Ratings Summary
CAH Quant Ranking